Dyslipidemia

A new study found a greater PCSK9 is associated with a greater cutaneous melanoma risk.

ORION-8 demonstrates the consistent long-term efficacy and tolerability of twice-yearly inclisiran over a mean cumulative exposure of 3.7 years.

Increases in metabolic risk factors like high blood pressure and BMI have led to a 49.4% increase in global disability-adjusted life years from 2000 to 2021.

A recent study suggests that high ultraprocessed food consumption in preschool children is linked to increased cardiometabolic risk factors.

Announced on May 22, 2024, the Roche Diagnostics Tina-quant® Lp(a) assay measures lipoprotein (a) in a person’s bloodstream to evaluate cardiovascular risk.

Data from a meta-analysis of evinacumab trials reveal significant reductions in cholesterol and other lipid markers among patients with dyslipidemia.

Study finds 2013 ACC/AHA guideline led to immediate improvements in optimal statin use for ASCVD patients and enhanced 5-year MACE survival for populations with ASCVD or diabetes in the US.

Transmasculine patients undergoing GAHT may experience adverse lipid profile changes, unlike transfeminine counterparts, which investigators say is cause for closer monitoring.

A systematic review and meta-analysis of 51 studies suggests elevated Lp(a) can help predict risk of premature atherosclerotic cardiovascular disease.

Nieca Goldberg, MD, discusses important news and updates in cardiovascular health among women from the early portions of 2024.

A new study highlights the potential of lipoprotein apheresis for reducing cardiovascular events in patients with elevated Lp(a).

The final in our 3-part quiz series based on the NLA's 2024 update to their 2019 scientific statement on use of lipoprotein(a) in clinical practice focuses on treatment considerations and therapeutic options for elevated Lp(a).

The April 2024 cardiology month in review spotlights FDA news and top updates from the American College of Cardiology 2024 Scientific Session.

An analysis of NHANES found aspirin's benefits in primary prevention may hinge on lipoprotein(a) (Lp(a)) levels, halving ASCVD mortality risk with Lp(a) ≥50 mg/dL.

The second in our 3-part quiz series based on the NLA's 2024 update to their 2019 scientific statement on use of lipoprotein(a) in clinical practice focuses on recommendations for patients.

The first in our 3-part quiz series based on the NLA's 2024 update to their 2019 scientific statement on use of lipoprotein(a) in clinical practice focuses on basic considerations surrounding Lp(a) measurement.

A new analysis of the REDUCE-IT trial reveals the benefits of icosapent ethyl in reducing cardiovascular outcomes regardless of LDL-C levels.

Olezarsen shows promise in managing familial chylomicronemia syndrome, reducing triglycerides and acute pancreatitis events.

Laura Ross, PA-C, sits down for a Q&A on the HeartBeet Clinic and the role of reimbursable group visits in cardiovascular disease management and education.

Deepak Bhatt, MD, MPH, MBA, provides a recap of top trials and new data from the American College of Cardiology's 2024 Annual Scientific Session.

A study on a web app for nonprescription statin therapy shows high concordance with clinician assessment, with 84.5% of participants achieving LDL-C reduction of 20% or more.

Christie Ballantyne, MD, discusses new data from the ROSE2 trial examining the potential synergistic effects of obicetrapib with ezetimibe in high-intensity statin users.

Christie Ballantyne, MD, discusses data from the SHASTA-2 trial and how it informs the community on the potential of plozasiran in management of severe hypertriglyceridemia.

Plozasiran demonstrates a 74% reduction in triglyceride levels at 24 weeks in patients with severe hypertriglyceridemia in the phase 2b SHASTA-2 trial.

New data from a phase 3b trial presented at ACC.24 underlines the potential of inclisiran in reducing LDL-C levels among patients with ASCVD.

CSL112 infusion did not reduce major cardiovascular events at 90 days but further analysis suggests patients with elevated LDL-C levels could derive significant benefit.

A recap of the biggest FDA news and decisions in cardiovascular medicine from the first 3 months of 2024, with commentary on recent announcements by Deepak Bhatt, MD, MPH, MBA.

Verve Therapeutics announced plans to voluntary pause enrollment of the Heart-1 trial, citing an adverse event and consultation with DSMB, with plans to shift focus to VERVE-102 and Heart-2 trial.

This clinical quiz will test your knowledge on management of LDL-C special populations with nonstatin therapies based on the ACC's 2022 expert clinical decision pathway.